National Jewish Health Secures Six Patents in 2010

In 2010, National Jewish Health was issued a total of six US patents. This number represents one of the best years on record for National Jewish, despite a severe decrease in the patent allowance rate by the USPTO in the last 10 years.

Historically, the US patent allowance rate has been stable, hovering between the low 60% and the low 70% from 1975 to 2000. However, after 2000, the allowance rate has been consistently declining to reach about 40% in 2009.

Patents issued to National Jewish Health in 2010:

National Jewish
Health Inventor
Title Patent No. Issue Date

 

Dr. Erwin Gelfand

 

Vaccines Using Nucleic Acid-Lipid Complexes

This patent claims a new kind of vaccine, which uses a small lipid bubble to deliver an antigen and DNA adjuvant.

 

7,741,300

 

06/22/2010

 

Dr. William Schiemann

 

Cystatin C as an Antagonist of TGF-B and Methods Related Thereto

This patent claims methods to identify CystC homologues that are antagonists or inhibitors of TGF-ß and compositions and therapeutic methods using CystC and homologues to regulate the activity of TGF-ß, and TGF-ß-mediated tumor malignancy.

 

7,749,958

 

07/06/2010

 

Dr. Donald Leung

 

Cationic Steroid Antimicrobial Compositions and Methods of Use

The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo.

 

7,754,705

 

07/13/2010

 

Dr. Ronald Harbeck

 

Method and Kit for Detection of Autoimmune Chronic Urticaria

This patent claims a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.

 

7,772,011

 

08/10/2010

 

Dr. John Cambier

 

Product and Method for Treatment of Conditions Associated with Receptor-Desensitization

This patent claims the use of antibodies to desensitize B cell antigen receptors on the surface of B cells. This method has therapeutic potential for the treatment of B cell-mediated disorders like autoimmune diseases (rheumatoid arthritis, lupus etc), cancer (B cell lymphoma for example) or organ transplant rejection.

 

7,825,224

 

11/02/2010

 

Dr. Gongyi Zhang

 

Three-dimensional structure of TALL-1 and its cognate receptors and modified proteins and methods related thereto

This patent relates to the use of the cytokine TALL-1 and its receptor homologues BCMA and BAFF-R as potential therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis or lupus.

 

7,825,089

 

11/02/2010

For a complete list of National Jewish Health patents click here.

Bookmark and Share

News Archive
Browse by Year

Search All

2014
|
2013
|
2012
|
Media Contacts

Newsroom

In the Newsroom, you can find National Jewish Health press releases, newsletters, annual reports and media contacts. Learn more.

 

Sign Up for e-Newsletters

Enter your email address to receive health tips, recent research findings and news about National Jewish Health.